Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
26 authors.
Cindy GutzeitDepartment of Medicine, Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0009-0008-8118-648X
Emilie K GrassetDepartment of Pediatrics, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0002-9592-1640
Dean B MatthewsImmunology Program of the Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Paul J MaglionePulmonary Center and Department of Medicine, Boston University, Boston, MA 02118, USA.ORCID 0000-0001-6805-7271
Graham J BrittonPrecision Immunology Institute, Icahn Institute for Data Science and Genome Technology, School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0003-4630-1223
Haley MillerDepartment of Medicine, Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Giuliana MagriProgram for Inflammatory and Cardiovascular Disorders, Institute Hospital del Mar for Medical Investigations (IMIM), 08003 Barcelona, Spain.ORCID 0000-0002-0163-3542
Lewis TomalinDepartment of Genetics and Genomic Sciences, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0003-4545-7138
Matthew StapyltonDepartment of Genetics and Genomic Sciences, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0009-0001-5516-5238
Pablo Canales-HerreriasDepartment of Medicine, Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0002-1865-6476
Musia SominskaiaDepartment of Pediatrics, Weill Cornell Medicine, New York, NY 10021, USA.
Mauricio GuzmanProgram for Inflammatory and Cardiovascular Disorders, Institute Hospital del Mar for Medical Investigations (IMIM), 08003 Barcelona, Spain.ORCID 0000-0002-4447-2064
Marc PybusMolecular Biology Laboratory, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), 02041 Barcelona, Spain.ORCID 0000-0002-6195-5738
Sonia Tejedor VaqueroProgram for Inflammatory and Cardiovascular Disorders, Institute Hospital del Mar for Medical Investigations (IMIM), 08003 Barcelona, Spain.ORCID 0000-0003-2873-4981
Lin RadiganDepartments of Medicine and Pediatrics, Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Roser Tachó-PiñotProgram for Inflammatory and Cardiovascular Disorders, Institute Hospital del Mar for Medical Investigations (IMIM), 08003 Barcelona, Spain.ORCID 0000-0002-4641-1134
Andrea Martín NaldaInfection in Immunocompromised Pediatric Patients Research Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.ORCID 0000-0002-3590-0186
Marina García PratInfection in Immunocompromised Pediatric Patients Research Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.ORCID 0000-0001-5387-1908
Monica Martinez GalloPediatric Infectious Diseases and Immunodeficiencies Unit, Vall d'Hebron University Hospital (HUVH), Barcelona Autònoma University (UAB), 48201 Barcelona, Spain.ORCID 0000-0002-7340-2161
Romina Dieli-CrimiDivision of Immunology, Vall d'Hebron University Hospital (HUVH), Barcelona Autònoma University (UAB), 48201 Barcelona, Spain.ORCID 0000-0003-3413-5133
José C ClementeDepartment of Medicine, Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Saurabh MehandruDepartment of Medicine, Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0001-9781-2969
Mayte Suarez-FarinasDepartment of Genetics and Genomic Sciences, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0001-8712-3553
Jeremiah J FaithDepartment of Medicine, Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0002-2691-4500
Charlotte Cunningham-RundlesDepartments of Medicine and Pediatrics, Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0003-0725-0320
Andrea CeruttiDepartment of Medicine, Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0003-3026-4704
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Regulation of IgA class switching in the intestinal mucosaP01AI061093 · NIAID · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI CASANOVA, JEAN-LAURENT · 2004 to 2021
$29.8M
Determination of mucosal immune responses to, and infection of the gastrointestinal tract by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)R01DK123749 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CERUTTI, ANDREA, FAITH, JEREMIAH JAMES · 2020 to 2024
$4.9M
Role of B cell activating factor in non-infectious complications of common variable immunodeficiencyK23AI137183 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MAGLIONE, PAUL JOSEPH · 2018 to 2022
$945k
Optimized identification of therapeutic bacterial strains in ulcerative colitisR01DK114038 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CLEMENTE, JOSE C · 2018 to 2020
$762k
Bacterial translocation to mesenteric adipose tissue drives pathogenic stromal-B cell interactions leading to inflammatory IgGR21AI168718 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI GRASSET, EMILIE K · 2023 to 2024
The gut microbiota enhances systemic immunoglobulin G (IgG) responses to vaccines, but it is unknown whether this effect involves IgA, which coats intestinal microbes. That IgA may amplify postimmune IgG production is suggested by the impaired IgG response to pneumococcal vaccines in some IgA-deficient patients. Here, we found that antipneumococcal but not total IgG production was impaired in mice with IgA deficiency. The positive effect of gut IgA on antipneumococcal IgG responses started very early in life and could implicate gut bacteria, as these responses were attenuated in germ-free mice recolonized with gut microbes from IgA-deficient donors. IgA could exert this effect by constraining the systemic translocation of gut antigens, which was associated with chronic immune activation, including T cell overexpression of programmed cell death protein 1 (PD-1). This inhibitory receptor may attenuate antipneumococcal IgG production by causing B cell hyporesponsiveness, which improved upon anti-PD-1 treatment. Thus, gut IgA functionally interacts with systemic IgG to enhance antipneumococcal vaccine responses.
Indexed as
Gastrointestinal MicrobiomeImmunoglobulin AImmunoglobulin GPneumococcal VaccinesAnimalsAntibodies, BacterialB-LymphocytesMicePneumococcal InfectionsProgrammed Cell Death 1 ReceptorStreptococcus pneumoniaeAntibodies, BacterialImmunoglobulin AImmunoglobulin GPneumococcal VaccinesProgrammed Cell Death 1 Receptor
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Gut IgA functionally interacts with systemic IgG to enhance antipneumococcal vaccine responses. · full record | OpenQuestion